{"id":812966,"date":"2022-08-08T19:14:24","date_gmt":"2022-08-08T17:14:24","guid":{"rendered":"https:\/\/15.161.165.86\/non-categorizzato\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/"},"modified":"2022-08-08T19:14:24","modified_gmt":"2022-08-08T17:14:24","slug":"clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/","title":{"rendered":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs"},"content":{"rendered":"First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity\nConfirmed partial response in one patient in the lowest (3.7 GBq) dose cohort\nRecruitment of third of four planned dose cohorts is ongoing\nInitiation of Phase 2 expansion cohorts in multiple tumor types anticipated in Q4 2022\nPhase 3 ATHENA trial evaluating Rubraca\u00ae (rucaparib) monotherapy versus placebo (ATHENA-MONO) in front-line maintenance treatment of ovarian cancer presented at 2022 ASCO Annual Meeting\nSimultaneous publication in the Journal of Clinical Oncology (JCO)\nPresented at Best of ASCO meeting series\nsNDA and Type II variation planned f
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-812966","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nClovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez\" \/>\n<meta property=\"og:description\" content=\"First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-08T17:14:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs\",\"datePublished\":\"2022-08-08T17:14:24+00:00\",\"dateModified\":\"2022-08-08T17:14:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\"},\"wordCount\":3409,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\",\"name\":\"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-08-08T17:14:24+00:00\",\"dateModified\":\"2022-08-08T17:14:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/","og_locale":"en_US","og_type":"article","og_title":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez","og_description":"First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/","og_site_name":"BeBeez","article_published_time":"2022-08-08T17:14:24+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/"},"author":{"name":"","@id":""},"headline":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs","datePublished":"2022-08-08T17:14:24+00:00","dateModified":"2022-08-08T17:14:24+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/"},"wordCount":3409,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/","name":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-08-08T17:14:24+00:00","dateModified":"2022-08-08T17:14:24+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clovis-oncology-announces-second-quarter-2022-operating-results-and-provides-update-on-clinical-development-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=812966"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812966\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=812966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=812966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=812966"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=812966"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=812966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}